In today’s session Biogen Inc (BIIB) recorded an unusually high (310) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious BIIB decrease. With 310 contracts traded and 30644 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: BIIB161021P00290000 closed last at: $2.2 or 35.3% down. About 914,048 shares traded hands. Biogen Inc (NASDAQ:BIIB) has risen 15.02% since March 1, 2016 and is uptrending. It has outperformed by 5.78% the S&P500.
Analysts await Biogen Inc (NASDAQ:BIIB) to report earnings on October, 19. They expect $4.98 EPS, up 11.16% or $0.50 from last year’s $4.48 per share. BIIB’s profit will be $1.09B for 15.63 P/E if the $4.98 EPS becomes a reality. After $5.21 actual EPS reported by Biogen Inc for the previous quarter, Wall Street now forecasts -4.41% negative EPS growth.
Biogen Inc (NASDAQ:BIIB) Ratings Coverage
Out of 16 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 10 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 63% are positive. Biogen Idec Inc. has been the topic of 29 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, October 22 by H.C. Wainwright. The stock of Biogen Inc (NASDAQ:BIIB) earned “Strong-Buy” rating by Raymond James on Tuesday, September 1. Argus Research maintained Biogen Inc (NASDAQ:BIIB) on Monday, July 27 with “Buy” rating. The firm has “Outperform” rating by RBC Capital Markets given on Monday, July 27. Bernstein initiated the stock with “Outperform” rating in Wednesday, June 29 report. Raymond James maintained the shares of BIIB in a report on Tuesday, August 2 with “Strong Buy” rating. The firm earned “Neutral” rating on Monday, July 27 by Robert W. Baird. H.C. Wainwright initiated the shares of BIIB in a report on Tuesday, August 11 with “Buy” rating. The firm earned “Buy” rating on Thursday, February 25 by Citigroup. The stock has “Neutral” rating given by Credit Suisse on Wednesday, January 20.
Insitutional Activity: The institutional sentiment increased to 1.03 in Q2 2016. Its up 0.04, from 0.99 in 2016Q1. The ratio is positive, as 77 funds sold all Biogen Inc shares owned while 300 reduced positions. 83 funds bought stakes while 307 increased positions. They now own 183.84 million shares or 8.46% less from 200.84 million shares in 2016Q1.
Montag & Caldwell Ltd Liability, a Georgia-based fund reported 1,100 shares. Td Asset Management owns 196,750 shares or 0.09% of their US portfolio. Equitec Proprietary Limited Liability last reported 0% of its portfolio in the stock. Regentatlantic Cap Ltd Liability Corporation, a New Jersey-based fund reported 4,929 shares. Provident Investment Management Inc holds 66,090 shares or 3.29% of its portfolio. Thompson Rubinstein Or holds 3.29% of its portfolio in Biogen Inc (NASDAQ:BIIB) for 34,963 shares. Delta Asset Mgmt Ltd Liability Tn accumulated 100 shares or 0% of the stock. Westfield Capital Mngmt Limited Partnership has 245,663 shares for 0.49% of their US portfolio. Tekla Cap Ltd Llc holds 4.45% of its portfolio in Biogen Inc (NASDAQ:BIIB) for 450,533 shares. Channing Capital owns 30,136 shares or 0.31% of their US portfolio. Martingale Asset Mgmt Limited Partnership has 23,792 shares for 0.1% of their US portfolio. The Texas-based Twin Tree Management L P has invested 0.04% in Biogen Inc (NASDAQ:BIIB). Moreover, Bnp Paribas Arbitrage has 0.13% invested in Biogen Inc (NASDAQ:BIIB) for 118,384 shares. Meridian holds 11,229 shares or 1.65% of its portfolio. Barclays Public Ltd has invested 0.06% of its portfolio in Biogen Inc (NASDAQ:BIIB).
Insider Transactions: Since April 6, 2016, the stock had 0 buys, and 6 sales for $10.24 million net activity. 27,570 shares were sold by DORSA CAROLINE, worth $8.66M on Thursday, September 22. SCANGOS GEORGE A sold 3,855 shares worth $1.12M. Koppel Adam had sold 102 shares worth $28,050.
Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The company has a market cap of $67.94 billion. The Firm operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. It has a 18.18 P/E ratio. The Firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis , ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.